Voluntary announcement - entering into of joint venture agreement
Filed with HKEX · Stock code 8329 · · 6 pages · English
Summary by 6ix AI
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. has announced the establishment of a joint venture agreement with Huikang Bio-technology, focusing on early cancer screening and in vitro diagnostics. Neptunus Changjian, a subsidiary of the Company, will hold a majority equity interest in the joint venture, which will operate as a limited liability company in China. The joint venture aims to integrate resources for research and development, enhancing operational efficiency and market coverage in the medical health sector. This announcement is made voluntarily and outlines the terms and governance structure of the joint venture agreement.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. on 6ix
Earlier from Shenzhen Neptunus Interlong Bio-Technique
- Company information sheet
- Supplemental announcement in relation to the proposed appointment of independent non-executive director
Later from Shenzhen Neptunus Interlong Bio-Technique
- Monthly return of equity issuer on movements in securities for the month ended 30 September 2026
- Notice of board meeting
- Monthly return of equity issuer on movements in securities for the month ended 31 October 2026
- (1) Proposed distribution of the special dividend; (2) proposed change of company name and registered address; (3) proposed amendments to the articles of association; and (4) closure of register of members
- - Proposed distribution of the Special dividend
Follow Shenzhen Neptunus Interlong Bio-Technique into a list and get an email when it puts out news.
Follow Shenzhen Neptunus Interlong Bio-Technique